Home / Market News / $DGX
benzinga Corporate Catalyst Impact 55/100 ● positive

Barclays Maintains Overweight on Quest Diagnostics, Raises Price Target to $260

Oct 7, 2026, 3:17 PM UTC · Primary ticker $DGX

Barclays analyst Luke Sergott has reiterated an 'Overweight' rating on Quest Diagnostics (DGX) and increased its price target from $250 to $260. This indicates a continued positive outlook from the analyst, suggesting potential upside for the stock.

Barclays analyst Luke Sergott maintained an 'Overweight' rating on Quest Diagnostics (DGX) and raised the price target from $250 to $260. This action signals continued confidence in the company's performance and future prospects from a prominent financial institution. For traders, this could be seen as a positive signal, potentially leading to increased buying interest in the short term. The long-term implication is that the analyst believes the company's fundamentals support a higher valuation. The key opportunity for traders is to capitalize on potential upward momentum following this analyst upgrade, though it's important to note that analyst ratings are just one factor in stock performance.

$DGX positive Analyst price target increase
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.